Format

Send to

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res. 2009;11(3):303. doi: 10.1186/bcr2250. Epub 2009 May 18.

Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

Author information

1
Indiana University Simon Cancer Center, Indianapolis, IN 46220, USA. bpschnei@iupui.edu

Abstract

Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting?

PMID:
19519950
PMCID:
PMC2716490
DOI:
10.1186/bcr2250
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center